Treatment of Relapsed Carcinoma of the Ovary with Single-Agent Paclitaxel Following Exposure to Paclitaxel and Platinum Employed as Initial Therapy
- 30 November 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 79 (2) , 211-215
- https://doi.org/10.1006/gyno.2000.5958
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Clinical Features of Hypersensitivity Reactions to CarboplatinJournal of Clinical Oncology, 1999
- Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Journal of Clinical Oncology, 1998
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agentGynecologic Oncology, 1985
- Reporting results of cancer treatmentCancer, 1981